Vanda Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vanda Pharmaceuticals Inc. on April 22, 2026. The report discloses a corporate governance event involving the expansion of the Board of Directors and the appointment of a new director.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figures disclosed relate to director compensation:
- Initial Restricted Stock Unit (RSU) Award: Fixed grant date value of $390,000 as of April 22, 2026.
- Annual Cash Fee: $50,000, payable quarterly.
- Future Annual RSU Award: Eligible for an additional award with a fixed grant date value of $260,000 upon conclusion of each annual meeting starting in 2026.
Material Changes
The Board of Directors expanded its size from six to seven members, effective immediately. Charles C. Duncan, Ph.D., was appointed as a Class II director to fill the vacancy. His initial term expires at the 2026 annual meeting of stockholders. The Board has determined Dr. Duncan is an independent director.
Guidance, Outlook, and Risks
This filing contains no guidance, outlook, or management commentary regarding the company's business operations or financial future. The filing notes that Dr. Duncan entered into a standard indemnification agreement with the Company. No related party transactions between the Company and Dr. Duncan have occurred since the beginning of the last fiscal year.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for additional context on the appointment.
- Review the upcoming Definitive Proxy Statement for the 2026 annual meeting for detailed terms of the outside director compensation program.
- Confirm the vesting schedule of the initial $390,000 RSU award (four equal installments, first vesting April 22, 2027).
- Note the change of control provision which triggers full vesting of all RSUs.